Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition

Despite the introduction of tyrosine kinase inhibitors, gastrointestinal stromal tumors (GIST) resistance remains a major clinical challenge. We previously identified phosphodiesterase 3A (PDE3A) as a potential therapeutic target expressed in most GIST. The PDE3 inhibitor cilostazol reduced cell via...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandenberghe, Pierre, Delvaux, Marine, Hagué, Perrine, Erneux, Christophe, Vanderwinden, Jean-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442998/
https://www.ncbi.nlm.nih.gov/pubmed/30956759
http://dx.doi.org/10.18632/oncotarget.26734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442998/
https://www.ncbi.nlm.nih.gov/pubmed/30956759
http://dx.doi.org/10.18632/oncotarget.26734

Ejemplares similares